Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Imunon (IMNN – Research Report). The associated price target was raised to $14.00.
Emily Bodnar’s rating is based on Imunon’s strategic advancements in their clinical trials and promising results from their ongoing research. The company is preparing to initiate a Phase 3 trial for IMNN-001 in combination with neoadjuvant chemotherapy for advanced ovarian cancer, which is set to enroll approximately 500 women. This trial builds on the success of the OVATION 2 trial, which showed a significant improvement in overall survival rates, and indicates strong interest from physicians familiar with the treatment.
Additionally, Imunon’s development of the IMNN-101 DNA plasmid vaccine for COVID-19 has shown positive initial results in terms of safety and immune response. The vaccine, designed using the company’s proprietary technology, demonstrated a sustained increase in neutralizing antibody titers and cross-reactivity against newer variants, suggesting broader protective potential. These factors collectively contribute to Bodnar’s Buy rating, reflecting confidence in Imunon’s innovative approaches and potential market impact.